Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael Scott Gordon, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R41MD012261 (VOCCI, FRANK J.) Sep 24, 2019 - Aug 31, 2020
    NIH/NIMHD
    The Daily Progress System - A Recovery Support Tool to Reduce Health Disparities in Outpatient Substance Use Treatment
    Role: Principal Investigator
  2. UG1DA050077 (GORDON, MICHAEL SCOTT) Jul 15, 2019 - Apr 30, 2024
    NIH
    A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail
    Role: Principal Investigator
  3. R01DA043476 (GORDON, MICHAEL SCOTT) Jul 15, 2018 - Apr 30, 2023
    NIH
    Buprenorphine for probationers and parolees: Bridging the gap into treatment
    Role: Principal Investigator
  4. R01DA040636 (GORDON, MICHAEL SCOTT) Aug 15, 2016 - Apr 30, 2022
    NIH
    Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment
    Role: Principal Investigator
  5. R41MD009540 (GORDON, MICHAEL SCOTT) Aug 1, 2015 - Jul 31, 2017
    NIH
    Avatar Assisted Therapy for Probationers and Parolees with Substance Use Disorders
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Gordon MS, Shapiro GI, Sarantopoulos J, Juric D, Lu B, Zarotiadou A, Connarn JN, Le Bruchec Y, Dumitru CD, Harvey RD. Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors. Front Oncol. 2021; 11:786120. PMID: 35070991.
    Citations:    
  2. Maurice-Dror C, Le Moigne R, Vaishampayan U, Montgomery RB, Gordon MS, Hong NH, DiMascio L, Perabo F, Chi KN. A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer. Invest New Drugs. 2022 Apr; 40(2):322-329. PMID: 34843005.
    Citations:    Fields:    
  3. Guigay J, Lee KW, Patel MR, Daste A, Wong DJ, Goel S, Gordon MS, Gutierrez M, Balmanoukian A, Le Tourneau C, Mita A, Vansteene D, Keilholz U, Schöffski P, Grote HJ, Zhou D, Bajars M, Penel N. Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial. J Immunother Cancer. 2021 10; 9(10). PMID: 34663640.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  4. Drenner K, Basu GD, Goodman LJ, Ozols AA, LoBello JR, Royce T, Gordon MS, Borazanci EH, Steinbach MA, Trent J, Sharma S. The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series. Oncotarget. 2021 Aug 31; 12(18):1836-1847. PMID: 34504655.
    Citations:    Fields:    
  5. Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, Mascioni A, Le W, Wilson I, Gordon MS, Wu AM, Ulaner GA, Wolchok JD, Postow MA, Pandit-Taskar N. CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody. J Nucl Med. 2021 Aug 19. PMID: 34413145.
    Citations: 4     Fields:    
  6. George S, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Razak AA, Gordon MS, Somaiah N, Jennings J, Meade J, Shi K, Su Y, Ruiz-Soto R, Janku F. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer. 2021 09; 155:236-244. PMID: 34391056.
    Citations:    Fields:    Translation:Humans
  7. Gordon MS, Nemunaitis J, Barve M, Wainberg ZA, Hamilton EP, Ramanathan RK, Sledge GW, Yue H, Morgan-Lappe SE, Blaney M, Kasichayanula S, Motwani M, Wang L, Naumovski L, Strickler JH. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2021 10; 20(10):1988-1995. PMID: 34315767.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  8. Wong DJ, Bauer TM, Gordon MS, Bene-Tchaleu F, Zhu J, Zhang X, Cha E. Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial. Clin Lung Cancer. 2021 Jul 20. PMID: 34456145.
    Citations: 1     Fields:    
  9. Crable EL, Blue TR, McKenzie M, Rich JD, Gordon MS. Effect of Case Management on HIV Outcomes for Community Corrections Population: Results of an 18-Month Randomized Controlled Trial. J Acquir Immune Defic Syndr. 2021 05 01; 87(1):755-762. PMID: 33492021.
    Citations:    Fields:    Translation:Humans
  10. Apolo AB, Ellerton JA, Infante JR, Agrawal M, Gordon MS, Aljumaily R, Gourdin T, Dirix L, Lee KW, Taylor MH, Schöffski P, Wang D, Ravaud A, Manitz J, Pennock G, Ruisi M, Gulley JL, Patel MR. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer. 2020 10; 8(2). PMID: 33037118.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  11. Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith DC, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel MR, Neuwirth RL, Enke A, Shou Y, Sedarati F, Faller DV, Burris HA. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br J Cancer. 2020 11; 123(11):1590-1598. PMID: 32913286.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  12. In GK, Poorman K, Saul M, O'Day S, Farma JM, Olszanski AJ, Gordon MS, Thomas JS, Eisenberg B, Flaherty L, Weise A, Daveluy S, Gibney G, Atkins MB, Vanderwalde A. Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases. Oncotarget. 2020 Aug 18; 11(33):3118-3128. PMID: 32913556.
    Citations: 4     Fields:    
  13. Chiang AC, Sequist LVD, Gilbert J, Conkling P, Thompson D, Marcoux JP, Gettinger S, Kowanetz M, Molinero L, O'Hear C, Fassò M, Lam S, Gordon MS. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. Clin Lung Cancer. 2020 09; 21(5):455-463.e4. PMID: 32586767.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  14. Murphy SM, Jeng PJ, Poole SA, Jalali A, Vocci FJ, Gordon MS, Woody GE, Polsky D. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials. Addict Sci Clin Pract. 2020 04 22; 15(1):15. PMID: 32321570.
    Citations: 2     Fields:    Translation:Humans
  15. Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, De Vos F, Van Cutsem E, Millholland JM, Brase JC, Rangwala F, Gasal E, Corcoran RB. BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clin Cancer Res. 2020 06 01; 26(11):2466-2476. PMID: 32047001.
    Citations: 4     Fields:    Translation:Humans
  16. Mita MM, LoRusso PM, Papadopoulos KP, Gordon MS, Mita AC, Ferraldeschi R, Keer H, Oganesian A, Su XY, Jueliger S, Tolcher AW. A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma. Clin Cancer Res. 2020 06 15; 26(12):2819-2826. PMID: 31900279.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  17. Sullivan RJ, Hollebecque A, Flaherty KT, Shapiro GI, Rodon Ahnert J, Millward MJ, Zhang W, Gao L, Sykes A, Willard MD, Yu D, Schade AE, Crowe K, Flynn DL, Kaufman MD, Henry JR, Peng SB, Benhadji KA, Conti I, Gordon MS, Tiu RV, Hong DS. A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. Mol Cancer Ther. 2020 02; 19(2):460-467. PMID: 31645440.
    Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
  18. O'Donnell PH, Arkenau HT, Sridhar SS, Ong M, Drakaki A, Spira AI, Zhang J, Gordon MS, Degboe AN, Gupta AK, Mukhopadhyay P, Huang W, Abdullah SE, Angra N, Roskos LK, Guo X, Friedlander T. Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. Cancer. 2020 01 15; 126(2):432-443. PMID: 31581306.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  19. Jameson GS, Borazanci E, Babiker HM, Poplin E, Niewiarowska AA, Gordon MS, Barrett MT, Rosenthal A, Stoll-D'Astice A, Crowley J, Shemanski L, Korn RL, Ansaldo K, Lebron L, Ramanathan RK, Von Hoff DD. Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical Trial. JAMA Oncol. 2019 Oct 03. PMID: 31580386.
    Citations: 22     Fields:    
  20. Gerber DE, Infante JR, Gordon MS, Goldberg SB, Martín M, Felip E, Martinez Garcia M, Schiller JH, Spigel DR, Cordova J, Westcott V, Wang Y, Shames DS, Choi Y, Kahn R, Dere RC, Samineni D, Xu J, Lin K, Wood K, Royer-Joo S, Lemahieu V, Schuth E, Vaze A, Maslyar D, Humke EW, Burris HA. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. Clin Cancer Res. 2020 01 15; 26(2):364-372. PMID: 31540980.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  21. Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, Ochoa de Olza M, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Clin Cancer Res. 2019 06 01; 25(11):3220-3228. PMID: 30770348.
    Citations: 69     Fields:    Translation:HumansCTClinical Trials
  22. Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019 01 01; 5(1):74-82. PMID: 30242306.
    Citations: 176     Fields:    Translation:HumansCTClinical Trials
  23. Soares WE, Wilson D, Gordon MS, Lee JD, Nunes EV, O'Brien CP, Shroff M, Friedmann PD. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. Drug Alcohol Depend. 2019 01 01; 194:482-486. PMID: 30522048.
    Citations: 2     Fields:    Translation:Humans
  24. Hellerstedt BA, Vogelzang NJ, Kluger HM, Yasenchak CA, Aftab DT, Ramies DA, Gordon MS, Lara P. Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma. Clin Lung Cancer. 2019 03; 20(2):74-81.e1. PMID: 30528315.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  25. Hussong AM, Gottfredson NC, Bauer DJ, Curran PJ, Haroon M, Chandler R, Kahana SY, Delaney JAC, Altice FL, Beckwith CG, Feaster DJ, Flynn PM, Gordon MS, Knight K, Kuo I, Ouellet LJ, Quan VM, Seal DW, Springer SA. Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populations. Drug Alcohol Depend. 2019 01 01; 194:59-68. PMID: 30412898.
    Citations: 3     Fields:    Translation:HumansPHPublic Health
  26. Babiker HM, Byron SA, Hendricks WPD, Elmquist WF, Gampa G, Vondrak J, Aldrich J, Cuyugan L, Adkins J, De Luca V, Tibes R, Borad MJ, Marceau K, Myers TJ, Paradiso LJ, Liang WS, Korn RL, Cridebring D, Von Hoff DD, Carpten JD, Craig DW, Trent JM, Gordon MS. E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. Invest New Drugs. 2019 08; 37(4):636-645. PMID: 30264293.
    Citations: 6     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  27. Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018 09; 101:201-209. PMID: 30077125.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  28. Grisham RN, Moore KN, Gordon MS, Harb W, Cody G, Halpenny DF, Makker V, Aghajanian CA. Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders. Clin Cancer Res. 2018 11 15; 24(22):5525-5533. PMID: 29844129.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  29. Shah MA, Starodub A, Sharma S, Berlin J, Patel M, Wainberg ZA, Chaves J, Gordon M, Windsor K, Brachmann CB, Huang X, Vosganian G, Maltzman JD, Smith V, Silverman JA, Lenz HJ, Bendell JC. Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. Clin Cancer Res. 2018 08 15; 24(16):3829-3837. PMID: 29691300.
    Citations: 39     Fields:    Translation:HumansCTClinical Trials
  30. Goss GD, Vokes EE, Gordon MS, Gandhi L, Papadopoulos KP, Rasco DW, Fischer JS, Chu KL, Ames WW, Mittapalli RK, Lee HJ, Zeng J, Roberts-Rapp LA, Loberg LI, Ansell PJ, Reilly EB, Ocampo CJ, Holen KD, Tolcher AW. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor. Cancer. 2018 05 15; 124(10):2174-2183. PMID: 29533458.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  31. Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018 04; 19(4):451-460. PMID: 29530667.
    Citations: 89     Fields:    Translation:HumansCTClinical Trials
  32. Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov. 2018 04; 8(4):428-443. PMID: 29431699.
    Citations: 164     Fields:    Translation:HumansCellsCTClinical Trials
  33. Nebot N, Arkenau HT, Infante JR, Chandler JC, Weickhardt A, Lickliter JD, Sarantopoulos J, Gordon MS, Mak G, St-Pierre A, Tang L, Mookerjee B, Carson SW, Hayes S, Grossmann KF. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours. Br J Clin Pharmacol. 2018 04; 84(4):764-775. PMID: 29243287.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  34. Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith CG, Kuo I, Gordon MS, Altice FL, Ouellet LJ, Cunningham WE, Young JD, Springer SA. Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A "Seek, Test, Treat, and Retain" Harmonization Consortium. AIDS Behav. 2017 Oct; 21(10):2945-2957. PMID: 28188460.
    Citations: 7     Fields:    Translation:Humans
  35. Diamond JR, Goff B, Forster MD, Bendell JC, Britten CD, Gordon MS, Gabra H, Waterhouse DM, Poole M, Ross Camidge D, Hamilton E, Moore KM. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers. Invest New Drugs. 2017 10; 35(5):627-633. PMID: 28283779.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  36. Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017 Feb 14; 116(4):432-440. PMID: 28103611.
    Citations: 26     Fields:    Translation:HumansCTClinical Trials
  37. Nance RM, Delaney JA, Golin CE, Wechsberg WM, Cunningham C, Altice F, Christopoulos K, Knight K, Quan V, Gordon MS, Springer S, Young J, Crane PK, Mayer KH, Mugavero MJ, Del Rio C, Kronmal RA, Crane HM. Co-calibration of two self-reported measures of adherence to antiretroviral therapy. AIDS Care. 2017 04; 29(4):464-468. PMID: 27910703.
    Citations: 4     Fields:    Translation:Humans
  38. Gordon MS, Herbst RS, Horn L, Soria JC, Gandhi L, Felip E, Sequist L, Spigel DR, Antonia SJ, Balmanoukian A, Cassier P, Liu B, Kowanetz M, O'Hear C, Fassò M, Sandler A, Gettinger SN. PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S309-S310. PMID: 27969529.
    Citations: 2     Fields:    
  39. Gordon MS, Gordon MB. Occult Langerhans Cell Histiocytosis Presenting with Papillary Thyroid Carcinoma, a Thickened Pituitary Stalk and Diabetes Insipidus. Case Rep Endocrinol. 2016; 2016:5191903. PMID: 27656301.
    Citations: 5     
  40. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016 09 10; 34(26):3119-25. PMID: 27269937.
    Citations: 305     Fields:    Translation:HumansCTClinical Trials
  41. Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med. 2016 Mar 31; 374(13):1232-42. PMID: 27028913.
    Citations: 116     Fields:    Translation:HumansPHPublic Health
  42. Infante JR, Mendelson DS, Burris HA, Bendell JC, Tolcher AW, Gordon MS, Gillenwater HH, Arastu-Kapur S, Wong HL, Papadopoulos KP. A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors. Invest New Drugs. 2016 Apr; 34(2):216-24. PMID: 26924128.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  43. McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fassò M, Wang YV, Zou W, Hegde PS, Fine GD, Powles T. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. J Clin Oncol. 2016 Mar 10; 34(8):833-42. PMID: 26755520.
    Citations: 213     Fields:    Translation:HumansCellsCTClinical Trials
  44. Young P, Gordon MS. Mental health screening in immigration detention: A fresh look at Australian government data. Australas Psychiatry. 2016 Feb; 24(1):19-22. PMID: 26755798.
    Citations: 12     Fields:    Translation:HumansPHPublic Health
  45. Mitchell SG, Willet J, Monico LB, James A, Rudes DS, Viglione J, Schwartz RP, Gordon MS, Friedmann PD. Community correctional agents' views of medication-assisted treatment: Examining their influence on treatment referrals and community supervision practices. Subst Abus. 2016; 37(1):127-33. PMID: 26860334.
    Citations: 17     Fields:    Translation:Humans
  46. Vocci FJ, Schwartz RP, Wilson ME, Gordon MS, Kinlock TW, Fitzgerald TT, O'Grady KE, Jaffe JH. Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners. Drug Alcohol Depend. 2015 Nov 01; 156:133-138. PMID: 26409751.
    Citations: 8     Fields:    Translation:Humans
  47. Gordon MS, Kinlock TW, Vocci FJ, Fitzgerald TT, Memisoglu A, Silverman B. A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners. J Subst Abuse Treat. 2015 Dec; 59:52-8. PMID: 26299956.
    Citations: 20     Fields:    Translation:Humans
  48. Green J, Melvin GA, Newman L, Jones M, Taffe J, Gordon M. Day program for young people with anorexia nervosa. Australas Psychiatry. 2015 Jun; 23(3):249-53. PMID: 25948510.
    Citations: 8     Fields:    Translation:Humans
  49. Eppler S, Gordon MS, Redfern CH, Trudeau C, Xu N, Han K, Lum BL. Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors. Anticancer Drugs. 2015 Apr; 26(4):448-55. PMID: 25643049.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  50. Solomon PM, Bryce BA, Kuroda MA, Keech R, Shetty S, Shaw TM, Copel M, Hung LW, Schrott AG, Armstrong C, Gordon MS, Reuter KB, Theis TN, Haensch W, Rossnagel SM, Miyazoe H, Elmegreen BG, Liu XH, Trolier-McKinstry S, Martyna GJ, Newns DM. Pathway to the piezoelectronic transduction logic device. Nano Lett. 2015 Apr 08; 15(4):2391-5. PMID: 25793915.
    Citations: 3     Fields:    
  51. Sarma A, Shyn PB, Vivian MA, Ng JM, Tuncali K, Lorch JH, Zaheer SN, Gordon MS, Silverman SG. Single-Session CT-Guided Percutaneous Microwave Ablation of Bilateral Adrenal Gland Hyperplasia Due to Ectopic ACTH Syndrome. Cardiovasc Intervent Radiol. 2015 Oct; 38(5):1335-8. PMID: 25762486.
    Citations: 2     Fields:    Translation:Humans
  52. Lee JD, Friedmann PD, Boney TY, Hoskinson RA, McDonald R, Gordon M, Fishman M, Chen DT, Bonnie RJ, Kinlock TW, Nunes EV, Cornish JW, O'Brien CP. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial. Contemp Clin Trials. 2015 Mar; 41:110-7. PMID: 25602580.
    Citations: 12     Fields:    Translation:HumansPHPublic Health
  53. Gordon MS, Springett GM, Su YB, Ould-Kaci M, Wind S, Zhao Y, LoRusso PM. A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors. Future Oncol. 2015; 11(10):1479-91. PMID: 25963426.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  54. Suttle AB, Grossmann KF, Ouellet D, Richards-Peterson LE, Aktan G, Gordon MS, LoRusso PM, Infante JR, Sharma S, Kendra K, Patel M, Pant S, Arkenau HT, Middleton MR, Blackman SC, Botbyl J, Carson SW. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. J Clin Pharmacol. 2015 Apr; 55(4):392-400. PMID: 25449654.
    Citations: 14     Fields:    Translation:Humans
  55. Dickson MA, Gordon MS, Edelman G, Bendell JC, Kudchadkar RR, LoRusso PM, Johnston SH, Clary DO, Schwartz GK. Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015 Apr; 33(2):349-56. PMID: 25476894.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  56. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27; 515(7528):563-7. PMID: 25428504.
    Citations: 2005     Fields:    Translation:HumansCellsCTClinical Trials
  57. Cox DS, Allred A, Zhou Y, Infante JR, Gordon MS, Bendell J, Jones S, Burris H, Orford K. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors. Clin Pharmacol Drug Dev. 2015 07; 4(4):287-94. PMID: 27136909.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  58. Xu N, Redfern CH, Gordon M, Eppler S, Lum BL, Trudeau C. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1251-60. PMID: 25344761.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  59. Kwong N, Marqusee E, Gordon MS, Larsen PR, Garber JR, Kim MI, Alexander EK. Long-term, treatment-free survival in select patients with distant metastatic papillary thyroid cancer. Endocr Connect. 2014 Dec; 3(4):207-14. PMID: 25316293.
    Citations: 8     
  60. Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS. An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014 Dec 01; 20(23):5918-26. PMID: 25261556.
    Citations: 36     Fields:    Translation:HumansCTClinical Trials
  61. Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol. 2014 Oct 20; 32(30):3391-9. PMID: 25225437.
    Citations: 54     Fields:    Translation:HumansCellsCTClinical Trials
  62. Gordon MS, Melvin GA. Do antidepressants make children and adolescents suicidal? J Paediatr Child Health. 2014 Nov; 50(11):847-54. PMID: 24941902.
    Citations: 2     Fields:    Translation:Humans
  63. Carvajal RD, Wong MK, Thompson JA, Gordon MS, Lewis KD, Pavlick AC, Wolchok JD, Rojas PB, Schwartz JD, Bedikian AY. A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. Eur J Cancer. 2014 Aug; 50(12):2099-107. PMID: 24930625.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  64. Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O'Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014 Sep 01; 142:33-40. PMID: 24962326.
    Citations: 38     Fields:    Translation:Humans
  65. Gordon M, Melvin G. Risk assessment and initial management of suicidal adolescents. Aust Fam Physician. 2014 Jun; 43(6):367-72. PMID: 24897985.
    Citations: 6     Fields:    Translation:Humans
  66. Mita M, Gordon M, Rosen L, Kapoor N, Choy G, Redkar S, Taverna P, Oganesian A, Sahai A, Azab M, Bristow R, Tolcher AW. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul; 74(1):195-204. PMID: 24849582.
    Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
  67. Gordon MS, Kinlock TW, Schwartz RP, Couvillion KA, Sudec LJ, O'Grady KE, Vocci FJ, Shabazz H. Buprenorphine Treatment for Probationers and Parolees. Subst Abus. 2015; 36(2):217-25. PMID: 24701967.
    Citations: 11     Fields:    Translation:Humans
  68. Gordon M, Melvin GA. Prescribing for depressed adolescents: office decision-making in the face of limited research evidence. J Paediatr Child Health. 2014 Jul; 50(7):498-503. PMID: 24617419.
    Citations: 1     Fields:    Translation:Humans
  69. Orsinger GV, Watson JM, Gordon M, Nymeyer AC, de Leon EE, Brownlee JW, Hatch KD, Chambers SK, Barton JK, Kostuk RK, Romanowski M. Simultaneous multiplane imaging of human ovarian cancer by volume holographic imaging. J Biomed Opt. 2014 Mar; 19(3):36020. PMID: 24676382.
    Citations: 3     Fields:    Translation:Humans
  70. Basch E, Autio KA, Smith MR, Bennett AV, Weitzman AL, Scheffold C, Sweeney C, Rathkopf DE, Smith DC, George DJ, Higano CS, Harzstark AL, Sartor AO, Gordon MS, Vogelzang NJ, de Bono JS, Haas NB, Corn PG, Schimmoller F, Scher HI. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. Eur Urol. 2015 Feb; 67(2):310-8. PMID: 24631409.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  71. Rosen LS, Gordon MS, Robert F, Matei DE. Endoglin for targeted cancer treatment. Curr Oncol Rep. 2014 Feb; 16(2):365. PMID: 24445497.
    Citations: 44     Fields:    Translation:Humans
  72. Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH, Puzanov I, Quinn DI, Flaig TW, VanVeldhuizen P, Byrnes-Blake K, Freeman JA, Bittner R, Hunder N, Souza S, Thompson JA. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer. 2014; 2:2. PMID: 24829759.
    Citations: 19     Fields:    
  73. Donaldson AE, Gordon MS, Melvin GA, Barton DA, Fitzgerald PB. Addressing the needs of adolescents with treatment resistant depressive disorders: a systematic review of rTMS. Brain Stimul. 2014 Jan-Feb; 7(1):7-12. PMID: 24527502.
    Citations: 17     Fields:    Translation:Humans
  74. Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2014 Jun; 12(3):167-177.e2. PMID: 24365125.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  75. Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res. 2014 Jan 15; 20(2):480-9. PMID: 24173543.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  76. Gordon MS, Melvin GA. Suicide risk assessment: where are we now? Med J Aust. 2013 Oct 21; 199(8):534. PMID: 24138374.
    Citations:    Fields:    Translation:Humans
  77. Wagner AJ, Chugh R, Rosen LS, Morgan JA, George S, Gordon M, Dunbar J, Normant E, Grayzel D, Demetri GD. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res. 2013 Nov 01; 19(21):6020-9. PMID: 24045182.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  78. Copel M, Kuroda MA, Gordon MS, Liu XH, Mahajan SS, Martyna GJ, Moumen N, Armstrong C, Rossnagel SM, Shaw TM, Solomon PM, Theis TN, Yurkas JJ, Zhu Y, Newns DM. Giant piezoresistive on/off ratios in rare-earth chalcogenide thin films enabling nanomechanical switching. Nano Lett. 2013 Oct 09; 13(10):4650-3. PMID: 24016226.
    Citations: 3